COMMUNIQUÉS West-GlobeNewswire

Ultimovacs ASA: Mandatory notification of trade by primary insider
22/03/2024
Oslo, March 22, 2024, Board member Henrik Schüssler and primary insider in Ultimovacs ASA, has today through FireH AS bought 50,000 shares in the company at a price of NOK 6.398 per share. Following this transaction, [...]
Retrieve Medical Holdings, Inc. (RMHI) Announces Study Update Results Utilizing Retrieve Dx ™ Software
22/03/2024
BEDMINSTER, N.J. , March 22, 2024 (GLOBE NEWSWIRE) -- Retrieve Medical Holdings, Inc. (RMHI), the developer of Retrieve Dx, a real-time, cloud-based CDI (Clinical Documentation Integrity) application that improves [...]
Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024
22/03/2024
Oak Ridge, TN, March 22, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR) , the global leader in blood volume measurement technology, announces an investor call to be held on Monday, March 25, 2024, at 4:00 p.m [...]
American Shared Hospital Services Announces Fourth Quarter 2023 Earnings Conference Call
22/03/2024
Conference Call on Thursday, March 28th at 12:00 pm ET / 9:00 am PT SAN FRANCISCO, March 22, 2024 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey [...]
Recce Pharmaceuticals Announces RECCE® Trademark Registered in Canada, Strengthening Global IP Portfolio
22/03/2024
SYDNEY, Australia, March 22, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced it has been issued a trademark [...]
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
22/03/2024
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular [...]
Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results
22/03/2024
BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results [...]
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
22/03/2024
Positive opinion serves as a basis for final decision for potential authorization from the European Commission (EC), expected within 67 days ISELIN, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. ( [...]
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium
22/03/2024
BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer [...]
Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
22/03/2024
Positive CHMP opinion based on robust Phase III data, including APPLY-PNH, demonstrating superior hemoglobin improvement in the absence of transfusions with Fabhalta compared to anti-C5 therapy 1-5 If approved, Fabhalta [...]
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
22/03/2024
Best-in-class preliminary Phase 2 data for HB-200 in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancers in the first line setting Expect updated Phase 2 data with [...]
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US
22/03/2024
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US Aarhus, Denmark, 22 March 2024 – NMD Pharma A/S, a clinical-stage biotech company [...]
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
22/03/2024
-Biologics License Application (BLA) for HAV™ Accepted by FDA on February 8, 2024- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August 10, 2024- -Raised approximately $43.1 million in [...]
Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
22/03/2024
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in ( [...]
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
22/03/2024
Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial. Conjunctival Staining improved as early as day 29 with a durable benefit throughout [...]
Change in Orion Group Executive Management Board: change in Orion's group-level functions
22/03/2024
ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS 22 MARCH 2024 at 12.30 EET Change in Orion Group Executive Management Board: change in Orion's group-level functions The following change [...]
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
22/03/2024
BEDMINSTER, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid [...]
The change negotiations concerning Orion’s Kuopio plant have been concluded – the company has decided to continue to explore the outsourcing of production at the plant
22/03/2024
ORION CORPORATION PRESS RELEASE 22 March 2024 at 12.00 EET The change negotiations concerning Orion’s Kuopio plant have been concluded – the company has decided to continue to explore the outsourcing of production at [...]
The Ensign Group, Inc. Declares Quarterly Dividend of $0.06 Per Share
22/03/2024
SAN JUAN CAPISTRANO, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior [...]

Pages